timothy sykes logo
TPST Stock Spikes As Tempest Therapeutics Expands In Vivo CAR-T Pipeline Thumbnail
G Google News

TPST Stock Spikes As Tempest Therapeutics Expands In Vivo CAR-T Pipeline

MATT MONACO•UPDATED SEP. 16, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Tempest Therapeutics Inc. stocks have been trading up by 44.1 percent following highly positive clinical trial progress news.

Key Takeaways

  • Tempest Therapeutics struck an exclusive option deal with Hebei Senlang Biotechnology for a CD7-targeted lentiviral in vivo CAR-T platform, including a dual-target BCMA/GPRC5D program in Phase 1 for relapsed/refractory multiple myeloma.
  • The company also secured rights to Senlang’s broader in‑body CAR-T platform for oncology and autoimmune diseases and raised about $2.5M via a warrant-based private placement, sending TPST up roughly 35% after-hours.
  • The Senlang platform is set to complement Tempest Therapeutics’ own CD7-targeted LNP in vivo CAR-T technology, expanding its “immune reset” strategy across blood cancers and autoimmune conditions.
  • Management plans to showcase TPST’s clinical-stage in vivo CAR-T platform and lead candidate TPST-4003 at the H.C. Wainwright Global Investment Conference, adding a near-term catalyst for traders watching TPST.

Candlestick Chart

Live Update At 09:18:39 EDT: On Wednesday, September 16, 2026 Tempest Therapeutics Inc. stock [NASDAQ: TPST] is trending up by 44.1%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempest Therapeutics, trading under ticker TPST, is still a classic early-stage biotech story: rich in pipeline headlines, thin on revenue, and burning cash fast. The latest quarterly numbers show a net loss of about $5.24M, or roughly -$0.34 per share, reflecting heavy spending on research, development, and overhead. Operating cash outflow came in near $2.78M, leaving Tempest with just over $1.22M in cash at the end of the period and working capital of about -$2.75M.

That’s a tight balance sheet. TPST carries around $6.27M in long-term debt and shows negative common equity of roughly -$1.09M. Financial strength ratios confirm the pressure: a current ratio near 0.4 and a quick ratio around 0.2 tell traders this is not a comfortably funded name.

More Breaking News

On the chart, TPST has been sliding from the $1.10–$1.14 area down into the mid-$0.70s over recent days, with the latest close near $0.76. Intraday, the stock has shown quick spikes above $1.20 that fail back toward $1.05–$1.10, signaling hot-money trading and weak hands. For active traders, TPST is a classic “news moves the stock” setup where liquidity, sentiment, and catalysts matter more than traditional valuation.

Why Traders Are Watching TPST Right Now

TPST just handed traders exactly what they look for in small-cap biotech: a clear catalyst, a story pivot, and a violent price reaction. Tempest Therapeutics announced an exclusive option agreement with Hebei Senlang Biotechnology for a CD7-targeted lentiviral in vivo CAR-T platform and a portfolio of candidates, including a dual-target BCMA/GPRC5D program already in Phase 1. That specific asset hits relapsed/refractory multiple myeloma, a serious blood cancer that gets a lot of attention in the CAR-T world.

For TPST, this is not a minor science update. It reshapes the whole narrative. Tempest Therapeutics already had its own CD7-targeted LNP in vivo CAR-T platform. By layering in Senlang’s lentiviral in vivo technology, TPST is building a two-pronged delivery stack instead of betting on a single approach. Traders should see this as a diversification play across both oncology and autoimmune diseases under Tempest’s “immune reset” theme.

The market reaction backs that up. On the same day Tempest Therapeutics locked in the exclusive option to license Senlang’s in‑body CAR-T platform, the company raised about $2.5M via a warrant-based private placement, and TPST ripped roughly 35% after-hours. That tells you how starved this ticker was for a credible growth story.

Still, traders know warrant deals often mean future dilution. So while TPST grabbed short-term fuel for the balance sheet, the structure can cap upside if those warrants hang overhead. Active traders will watch how TPST trades around the H.C. Wainwright conference, where Tempest Therapeutics plans to highlight TPST-4003 and explain how the Senlang assets fit into its broader in vivo CAR-T roadmap. Any hint of timelines, data readouts, or partnering interest can spark another round of momentum trading.

Conclusion

TPST is stepping out of the micro-cap shadows with a louder in vivo CAR-T story, but it remains a high-risk, catalyst-driven trading vehicle. Tempest Therapeutics is still losing over $5M a quarter, carrying negative equity and a weak liquidity profile, and relying on capital raises like the recent $2.5M warrant-based private placement to stay in the game. That’s the reality traders need to keep front and center.

Against that backdrop, the Senlang deal is a big swing. By securing an exclusive option on a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform, plus a Phase 1 BCMA/GPRC5D multiple myeloma program, Tempest Therapeutics gives TPST a more compelling story than the average sub-$1 biotech ticker. The fact that TPST already runs its own CD7-targeted LNP in vivo CAR-T platform makes this look like a deliberate attempt to build a full “immune reset” toolkit, not a random asset grab.

For short-term traders, the 35% after-hours spike shows how quickly sentiment can flip when a tiny biotech like TPST lands a material deal. In fast-moving names like this, discipline matters as much as the headline: As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”. The next real test comes with follow-through price action, conference commentary, and any early hints of clinical traction. As Tim Sykes likes to say, “The market rewards preparation, not prediction.” With TPST, that means knowing the balance sheet, understanding the CAR-T story, and being ready to cut losses fast if the momentum fades. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”